The estimated Net Worth of Tobin Schilke is at least $4.44 Milion dollars as of 15 March 2024. Mr. Schilke owns over 9,361 units of Revance Therapeutics Inc stock worth over $1,267,742 and over the last 8 years he sold RVNC stock worth over $2,166,225. In addition, he makes $1,007,260 as Chief Financial Officer at Revance Therapeutics Inc.
Sign up
Mr. Schilke RVNC stock SEC Form 4 insiders trading
Tobin has made over 16 trades of the Revance Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 9,361 units of RVNC stock worth $47,179 on 15 March 2024.
The largest trade he's ever made was selling 21,401 units of Revance Therapeutics Inc stock on 2 February 2022 worth over $739,405. On average, Tobin trades about 1,629 units every 54 days since 2016. As of 15 March 2024 he still owns at least 192,666 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Schilke stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tobin Schilke biography
Tobin C. Schilke serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since November 2018. Mr. Schilke served as Chief Financial Officer of Achaogen, Inc. from July 2016 through October 2018. From 2002 to June 2016, Mr. Schilke served in roles of increasing responsibility at the Roche Group (including Genentech), a pharmaceutical company, including serving as Finance Director and Company Director of Roche Products Limited in the United Kingdom from August 2014 to June 2016 and serving as Director of Genentech's Commercial Finance BioOncology Business Unit from September 2012 to August 2014. Mr. Schilke holds a B.S. from Lafayette College. a M.S. from the University of California, Berkeley and an M.B.A. from Cornell University's Johnson Graduate School of Management.
What is the salary of Tobin Schilke?
As the Chief Financial Officer of Revance Therapeutics Inc, the total compensation of Tobin Schilke at Revance Therapeutics Inc is $1,007,260. There are 2 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of $17,190,400.
How old is Tobin Schilke?
Tobin Schilke is 45, he's been the Chief Financial Officer of Revance Therapeutics Inc since 2018. There are 12 older and 3 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
What's Tobin Schilke's mailing address?
Tobin's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli a Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Mr. Schilke stock trades at Revance Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director